









Markets
/
Stocks
/
nasdaq-anix
/

Anixa Biosciences Inc

ANIX

2.960USD

+0.210+7.64%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

97.72MMarket Cap

LossP/E TTM



Anixa Biosciences Inc

2.960

+0.210+7.64%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Anixa Biosciences Inc

Currency: USD Updated: 2026-02-06

Key Insights

Anixa Biosciences Inc's fundamentals are relatively very weak, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 173 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Anixa Biosciences Inc's Score

Industry at a Glance

Industry Ranking

173 / 392

Overall Ranking

326 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Anixa Biosciences Inc Highlights

StrengthsRisks

Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The Company's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The Company is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.

Fairly Valued

The company’s latest PE is -8.79, at a medium 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 42.76K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.37.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

10.000

Target Price

+263.64%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Anixa Biosciences Inc is 4.67, ranking 387 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

4.67

Change



Financials

1.96

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.55

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.53

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.57

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

6.73

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Anixa Biosciences Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Anixa Biosciences Inc is 6.66, ranking 241 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -8.79, which is -38.44% below the recent high of -5.41 and -80.30% above the recent low of -15.85.

Score

Industry at a Glance

Previous score

6.66

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 173/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Anixa Biosciences Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 9.50, with a high of 14.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

10.000

Target Price

+263.64%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Anixa Biosciences Inc

ANIX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Anixa Biosciences Inc is 6.82, ranking 162 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.44 and the support level at 2.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.37

Change

0.45

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.001

Sell

RSI(14)

42.257

Neutral

STOCH(KDJ)(9,3,3)

32.344

Buy

ATR(14)

0.170

High Vlolatility

CCI(14)

-107.237

Sell

Williams %R

65.000

Sell

TRIX(12,20)

-0.627

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

2.922

Buy

MA10

2.995

Sell

MA20

3.117

Sell

MA50

3.564

Sell

MA100

3.781

Sell

MA200

3.402

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Anixa Biosciences Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 17.72%, representing a quarter-over-quarter decrease of 0.74%. The largest institutional shareholder is The Vanguard, holding a total of 1.46M shares, representing 4.37% of shares outstanding, with 1.07% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

1.42M

+2.11%

Titterton (Lewis H Jr)

969.33K

+1.68%

Kumar (Amit)

610.49K

+5.27%

Laird Norton Wealth Management

597.24K

-3.24%

D.A. Davidson & Co.(Research)

614.27K

UBS Financial Services, Inc.

474.48K

-6.10%

Geode Capital Management, L.L.C.

343.64K

+0.24%

BofA Global Research (US)

213.96K

+1.73%

Mission Wealth Management, LP

356.15K

-3.62%

BlackRock Institutional Trust Company, N.A.

155.29K

+1.54%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Anixa Biosciences Inc is 2.29, ranking 239 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.50. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.